Venture capital-backed Capsida Biotherapeutics has appointed Susan Catalano as chief scientific officer.
The Californian company is working on a next-generation gene therapy platform which it hopes will lead to the development of novel therapeutics for rare and common diseases, selectively targeting specific organ systems.
Capsida has wholly-owned programs targeting central nervous system (CNS) disorders, as well as several strategic collaborations, including with Eli Lilly (NYSE: LLY) and with CRISPR Therapeutics (Nasdaq: CRSP).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze